Sivik Global Healthcare LLC Makes New Investment in Inspire Medical Systems, Inc. $INSP

Key Points

• Sivik Global Healthcare LLC has made a new investment in Inspire Medical Systems, purchasing 10,000 shares valued at approximately $1.3 million.
• Inspire Medical Systems reported a quarterly earnings per share of $0.45, surpassing analysts' expectations and achieving a 10.8% year-over-year revenue growth.
• The company has initiated a $200 million share buyback program, indicating that the board believes its shares are undervalued.

Sivik Global Healthcare LLC bought a new position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,000 shares of the company's stock, valued at approximately $1,298,000.

Several other large investors have also added to or reduced their stakes in the stock. Quarry LP boosted its position in shares of Inspire Medical Systems by 2,127.3% during the 1st quarter. Quarry LP now owns 245 shares of the company's stock valued at $39,000 after acquiring an additional 234 shares during the last quarter. Banque Transatlantique SA bought a new stake in shares of Inspire Medical Systems during the 1st quarter valued at about $46,000. Smartleaf Asset Management LLC boosted its position in shares of Inspire Medical Systems by 27.2% during the 1st quarter. Smartleaf Asset Management LLC now owns 454 shares of the company's stock valued at $71,000 after acquiring an additional 97 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Inspire Medical Systems by 14.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 603 shares of the company's stock valued at $78,000 after acquiring an additional 77 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Inspire Medical Systems by 253.7% during the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company's stock valued at $91,000 after acquiring an additional 411 shares during the last quarter. Institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Trading Down 6.1%

Shares of NYSE INSP opened at $75.23 on Friday. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of 43.49, a P/E/G ratio of 2.34 and a beta of 1.16. Inspire Medical Systems, Inc. has a 1-year low of $70.77 and a 1-year high of $216.01. The stock's 50-day moving average is $84.07 and its 200 day moving average is $121.52.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.23. The company had revenue of $217.09 million for the quarter, compared to analysts' expectations of $214.50 million. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.Inspire Medical Systems's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period last year, the firm posted $0.32 EPS. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. On average, analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems declared that its Board of Directors has approved a share buyback program on Monday, August 11th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 8.6% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INSP. Weiss Ratings reiterated a "sell (d)" rating on shares of Inspire Medical Systems in a research report on Wednesday. UBS Group set a $89.00 price target on Inspire Medical Systems and gave the company a "neutral" rating in a research report on Monday, September 22nd. Lake Street Capital set a $150.00 price target on Inspire Medical Systems and gave the company a "buy" rating in a research report on Tuesday, August 5th. Wall Street Zen downgraded Inspire Medical Systems from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, Piper Sandler decreased their price objective on Inspire Medical Systems from $233.00 to $150.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $150.50.

Insider Buying and Selling

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $93.39, for a total value of $1,027,290.00. Following the transaction, the chief financial officer directly owned 44,867 shares of the company's stock, valued at $4,190,129.13. The trade was a 19.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is owned by company insiders.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.